Sunshine Biopharma IncNASDAQ:SBFM
- LAST PRICE2.6300
- TODAY'S CHANGE (%)0.0200 (0.7663%)
- Bid / Lots2.6200/ 4
- Ask / Lots2.6500/ 1
- Open / Previous Close2.6200 / 2.6100
- Day Range
- 52 Week Range
- Volume104,117
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SBFM |
|---|---|---|
| 09:32 ET | 144 | 2.62 |
| 09:35 ET | 2759 | 2.66 |
| 09:37 ET | 492 | 2.62 |
| 09:39 ET | 2695 | 2.62 |
| 09:42 ET | 1007 | 2.63 |
| 09:53 ET | 210 | 2.65 |
| 09:57 ET | 650 | 2.632 |
| 10:00 ET | 445 | 2.64 |
| 10:04 ET | 2200 | 2.66 |
| 10:08 ET | 700 | 2.69 |
| 10:09 ET | 1300 | 2.69 |
| 10:11 ET | 185 | 2.675 |
| 10:15 ET | 600 | 2.69 |
| 10:20 ET | 900 | 2.7 |
| 10:31 ET | 1800 | 2.73 |
| 10:36 ET | 2400 | 2.69 |
| 10:45 ET | 189 | 2.6895 |
| 10:47 ET | 1000 | 2.71 |
| 10:49 ET | 200 | 2.6944 |
| 10:54 ET | 200 | 2.68 |
| 10:58 ET | 4190 | 2.66 |
| 11:00 ET | 300 | 2.65 |
| 11:02 ET | 100 | 2.65 |
| 11:14 ET | 180 | 2.65 |
| 11:16 ET | 300 | 2.65 |
| 11:18 ET | 2131 | 2.66 |
| 11:20 ET | 100 | 2.66 |
| 11:41 ET | 1400 | 2.64 |
| 11:43 ET | 1815 | 2.63 |
| 11:48 ET | 1058 | 2.64 |
| 11:57 ET | 100 | 2.6383 |
| 12:03 ET | 1031 | 2.64 |
| 12:06 ET | 750 | 2.635 |
| 12:08 ET | 700 | 2.6399 |
| 12:12 ET | 200 | 2.635 |
| 12:14 ET | 266 | 2.64 |
| 12:15 ET | 160 | 2.6223 |
| 12:17 ET | 7478 | 2.62 |
| 12:19 ET | 2178 | 2.6177 |
| 12:21 ET | 2729 | 2.61 |
| 12:35 ET | 3045 | 2.605 |
| 12:37 ET | 2100 | 2.6 |
| 12:39 ET | 5187 | 2.62 |
| 12:46 ET | 600 | 2.6175 |
| 12:48 ET | 100 | 2.62 |
| 12:50 ET | 100 | 2.6238 |
| 01:00 ET | 9408 | 2.59 |
| 01:02 ET | 200 | 2.605 |
| 01:06 ET | 100 | 2.5949 |
| 01:13 ET | 100 | 2.6078 |
| 01:26 ET | 1000 | 2.61 |
| 01:27 ET | 127 | 2.64 |
| 01:42 ET | 200 | 2.6019 |
| 01:49 ET | 1068 | 2.6 |
| 01:56 ET | 600 | 2.605 |
| 02:00 ET | 1272 | 2.61 |
| 02:05 ET | 100 | 2.61 |
| 02:07 ET | 1200 | 2.62 |
| 02:09 ET | 100 | 2.62 |
| 02:20 ET | 3200 | 2.62 |
| 02:25 ET | 200 | 2.63 |
| 02:27 ET | 100 | 2.64 |
| 02:30 ET | 5077 | 2.65 |
| 02:39 ET | 1000 | 2.64 |
| 02:41 ET | 100 | 2.63 |
| 03:06 ET | 500 | 2.62 |
| 03:12 ET | 734 | 2.62 |
| 03:17 ET | 120 | 2.63 |
| 03:21 ET | 3105 | 2.63 |
| 03:37 ET | 1000 | 2.63 |
| 03:48 ET | 100 | 2.63 |
| 03:51 ET | 400 | 2.64 |
| 04:00 ET | 1195 | 2.63 |
Nov 6, 2024
Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%, from 8:02AM ET on Wednesday Nov 06, 2024 by Dow Jones
8:02AM ET on Wednesday Nov 06, 2024 by Dow JonesSunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%, from 8:02AM ET on Wednesday Nov 06, 2024 by Dow Jones
8:02AM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sunshine Biopharma Inc | 5.2M | 0.0x | --- |
cbdMD Inc | 1.8M | 0.0x | --- |
Cyanotech Corp | 3.8M | -0.7x | --- |
Gelesis Holdings Inc | 7.3K | 0.0x | --- |
Synovics Pharmaceuticals Inc | 3.0K | 0.0x | --- |
Neurobiological Technologies Inc | 2.7K | 0.0x | --- |
Company Information
Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has over 32 additional generic prescription drugs. In addition, the Company is conducting a proprietary drug development program which consists of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). It also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio of pharmaceutical products consisting of approximately 61 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.
Contact Information
- Headquarters
- 333 Las Olas Way, Cu4 Suite 433FORT LAUDERDALE, FL, United States 33301
- Phone
- 954-515-0810
- Fax
- 514-426-6101
Executives
- Chairman of the Board, President, Chief Executive Officer
- Steve Slilaty
- Chief Financial Officer, Secretary
- Camille Sebaaly
- Chief Operating Officer
- Marc Beaudoin
- Chief Science Officer, Director
- Abderrazzak Merzouki
- Chief Development Officer
- Malek Chamoun
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.2M |
|---|---|
Revenue (TTM) | $30.5M |
Shares Outstanding | 2.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.99 |
EPS | $-194.01 |
Book Value | $1,513.73 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -15.20% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
